AEye Surges on Analyst Upgrade as Lidar Turnaround Hopes Grow
Technology Sarah Chen

AEye Surges on Analyst Upgrade as Lidar Turnaround Hopes Grow

AEye surged over 30% after Craig-Hallum initiated coverage with a buy rating and $3.50 target, spotlighting a potential turnaround. The lidar maker faces revenue challenges but adds new operations head.

AEYE
Nasdaq Hits Record as Intel AI Outlook Fuels Chip Rally, Dow Dips
Markets Daniel Marsh

Nasdaq Hits Record as Intel AI Outlook Fuels Chip Rally, Dow Dips

The Nasdaq hit a new intraday high Friday as Intel's strong Q2 outlook sparked a broad chip rally, while the Dow slipped. Consumer sentiment hit a record low, keeping inflation worries front and center.

INTC AMD ARM NVDA QQQ SPY DIA USO GLD
Snowflake Shares Tumble as AI Initiatives Face Software Sector Headwinds
Technology Sarah Chen

Snowflake Shares Tumble as AI Initiatives Face Software Sector Headwinds

Snowflake shares dropped 5.5% to $138.42, pressured by a software sector selloff and a class-action deadline. The company is expanding its AI offerings, but investors remain cautious about AI's effect on revenue.

SNOW IBM NOW
Eos Energy Q1 Earnings Set for May 13 After Revenue Preview, EOSE Stock Surges
Earnings James Calloway

Eos Energy Q1 Earnings Set for May 13 After Revenue Preview, EOSE Stock Surges

Eos Energy Enterprises will report Q1 results on May 13 after previewing $56M-$57M revenue and 17% shipment growth. Shares rose 12% on AI power deal with TURBINE-X.

EOSE
Charter Communications Shares Tumble 22% as Broadband Losses Double
Earnings James Calloway

Charter Communications Shares Tumble 22% as Broadband Losses Double

Charter Communications shares fell 22% after reporting 120,000 broadband customer losses in Q1, double last year's figure and worse than analyst expectations.

CHTR CMCSA
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Markets Daniel Marsh

Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data

Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.

LLY NVO
Cheetah Net Soars on Acquisition Deal, Heavy Trading Volume
Markets Daniel Marsh

Cheetah Net Soars on Acquisition Deal, Heavy Trading Volume

Cheetah Net shares jumped on heavy volume after agreeing to buy Super International Trading for $4.98M in cash, with a $10M annual revenue target.

CTNT
Keel Infrastructure Sells Paraguay Site for $13M, Exits Latin America
Crypto Sarah Chen

Keel Infrastructure Sells Paraguay Site for $13M, Exits Latin America

Keel Infrastructure sold its Paraguay facility for $13M, less than half the original price, completing its Latin American exit and shift toward AI data centers.

BITF
Tempus AI Partners with USC Health System, Unlocking Access to 1.5 Million Annual Visits
Technology Sarah Chen

Tempus AI Partners with USC Health System, Unlocking Access to 1.5 Million Annual Visits

Tempus AI Inc. partners with USC's Keck School of Medicine to deploy its molecular testing and trial-matching platform across a health system seeing 1.5 million patient visits each year.

TEM
FreeCast Soars on DIRECTV Multifamily Deal, Financing Risks Remain
Markets Daniel Marsh

FreeCast Soars on DIRECTV Multifamily Deal, Financing Risks Remain

FreeCast shares jumped 23.8% on a DIRECTV multifamily deal. Maxim Group initiated with Buy and $6 target. Dilution risks persist per SEC filings.

Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Markets Daniel Marsh

Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race

Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.

NVO LLY
Nvidia Nears All-Time High as Vera Rubin AI Platform Fuels 2027 Demand Hopes
Technology Sarah Chen

Nvidia Nears All-Time High as Vera Rubin AI Platform Fuels 2027 Demand Hopes

Nvidia shares surged 4.7% to $209.07, nearing record highs ahead of its May 20 earnings report, as investors eye demand for the upcoming Vera Rubin AI platform and cloud spending into 2027.

NVDA INTC GOOGL AVGO AMD ARM